December 01, 1996; 47 (6 Suppl 3) Articles
Modulation of gene expression rather than monoamine oxidase inhibition
(-)-Deprenyl-related compounds in controlling neurodegeneration
W. G. Tatton
First published December 1, 1996, DOI: https://doi.org/10.1212/WNL.47.6_Suppl_3.171S
Modulation of gene expression rather than monoamine oxidase inhibition
(-)-Deprenyl-related compounds in controlling neurodegeneration
W. G. Tatton
Neurology Dec 1996, 47 (6 Suppl 3) 171S-183S; DOI: 10.1212/WNL.47.6_Suppl_3.171S
Citation Manager Formats
Make Comment
See Comments

Article Information
vol. 47 no. 6 Suppl 3 171S-183S
Print ISSN:
Online ISSN:
History:
- First Published December 1, 1996.
Copyright & Usage:
Copyright 1996 by Advanstar Communications Inc.
Author Disclosures
- W. G. Tatton, MD, PhD, FRCPC, Chalmers-Redman, R.M.E., PhD
- W. G. Tatton, MD, PhD, FRCPC, Chalmers-Redman, R.M.E., PhD
- From the Departments of Physiology/Biophysics (Drs. Tatton and Chalmers-Redman), Psychology (Dr. Tatton), and the Institute for Neuroscience (Drs. Tatton and Chalmers-Redman), Dalhousie University, Halifax, Nova Scotia, Canada.
- Address correspondence and reprint requests to Dr. William G. Tatton, Institute for Neuroscience, 12th Floor Tupper Medical Building, Dalhousie University, Halifax, Nova Scotia, Canada, B3H4H7.
Article usage
Cited By...
Letters: Rapid online correspondence
No comments have been published for this article.
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
- Article
- Abstract
- The hypothetical basis for the benefits of MAO-B inhibition in Parkinson's disease.
- Clinical benefits of (-)-deprenyl.
- (-)-Deprenyl can increase neuronal survival in vivo and in vitro without inhibiting MAO-B.
- Apoptosis may be involved in neurodegeneration.
- Genes and proteins that promote or retard apoptosis.
- Evidence that mitochondria contribute to the initiation of apoptosis and that (-)-deprenyl alters apoptosis through a mitochondrial mechanism.
- (-)-Deprenyl alters the expression of genes that influence mitochondrial viability.
- Do the selective changes in gene expression explain the capacity of (-)-deprenyl to maintain mitochondrial membrane potential and reduce neuronal apoptosis?
- Do the actions of (-)-deprenyl on gene expression contribute to the benefits reported for (-)-deprenyl treatment in human neurodegenerative diseases?
- REFERENCES
- Figures & Data
- Info & Disclosures
Advertisement
Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study
Dr. Robert Shapiro and Dr. Amynah Pradhan
Related Articles
- No related articles found.